Literature DB >> 14619264

Addressing risk preferences in cost-effectiveness analyses.

Joshua Graff Zivin1, John F Bridges.   

Abstract

Cost-effectiveness analysis is a form of economic evaluation that compares that compares the costs and effectiveness of health interventions, where effectiveness is measured in a single scale. Despite the growth in the popularity of cost-effectiveness analysis, very few cost-effectiveness analyses adequately measure and account for uncertainty. In the health economics literature, two schools of thought are emerging. The first takes a statistical approach to uncertainty by focusing on the likelihood that a decision making error will be made. The second approach applies and develops economic theories of risk preference that consider the welfare implications for a patient when they are presented with interventions that have uncertain health outcomes. Cost-effectiveness analyses need to account for risk preferences if they claim to be increasing patient welfare.

Entities:  

Mesh:

Year:  2002        PMID: 14619264

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  4 in total

1.  Future challenges for the economic evaluation of healthcare: patient preferences, risk attitudes and beyond.

Authors:  John F P Bridges
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

3.  Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches.

Authors:  Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2022-02-09       Impact factor: 4.558

4.  Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve.

Authors:  Pedram Sendi
Journal:  Pharmacoeconomics       Date:  2020-10-31       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.